HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
about
CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcriptionHuman immunodeficiency virus type 1 Tat increases the expression of cleavage and polyadenylation specificity factor 73-kilodalton subunit modulating cellular and viral expressionRNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryoThree functional classes of transcriptional activation domainMutations in the carboxy-terminal domain of TBP affect the synthesis of human immunodeficiency virus type 1 full-length and short transcripts similarlyTranscription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivityC-terminal domain phosphatase sensitivity of RNA polymerase II in early elongation complexes on the HIV-1 and adenovirus 2 major late templatesHIV-1 Tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear Tat-interacting protein of 110 kDa, Tip110Association of Tat with purified HIV-1 and HIV-2 transcription preinitiation complexesThe Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKRThe human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoterA chromatin landmark and transcription initiation at most promoters in human cellsTranscription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitroP-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase IIA novel glutamine-RNA interaction identified by screening libraries in mammalian cells.Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytesCell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.Robust growth of human immunodeficiency virus type 1 (HIV-1)A nucleolar TAR decoy inhibitor of HIV-1 replication.The RNA element encoded by the trans-activation-responsive region of human immunodeficiency virus type 1 is functional when displaced downstream of the start of transcription.P-TEFb kinase recruitment and function at heat shock lociTranscriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation.Sarkosyl block of transcription reinitiation by RNA polymerase II as visualized by the colliding polymerases reinitiation assay.Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity.Potentiation of human immunodeficiency virus type 1 Tat by human cellular proteins.NELF-mediated stalling of Pol II can enhance gene expression by blocking promoter-proximal nucleosome assembly.Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex.Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapyCharacterization of a major histocompatibility complex class II X-box-binding protein enhancing tat-induced transcription directed by the human immunodeficiency virus type 1 long terminal repeatInteraction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes.Effects of heterologous downstream sequences on the activity of the HIV-1 promoter and its response to Tat.Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.RNA-targeted activators, but not DNA-targeted activators, repress the synthesis of short transcripts at the human immunodeficiency virus type 1 long terminal repeat.RNA polymerase mutations that impair conversion to a termination-resistant complex by Q antiterminator proteins.Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts.The HIV-1 inducer of short transcripts activates the synthesis of 5,6-dichloro-1-beta-D-benzimidazole-resistant short transcripts in vitro.
P2860
Q24315725-F6C12472-9E8F-4823-ABE7-4C108010E67CQ24564662-CB6188E7-71A8-4BB4-B0EE-AA6D9A966C65Q24645367-7D554940-4552-439A-82E4-2CEAD5255996Q24649917-C97E4893-BC89-4EEB-BD11-C95324A6453EQ24682057-C4FE9ABB-6F7C-46FF-8FE9-CFFBF42F9205Q24815940-6D0B6BBB-9AFA-4016-ADA3-F3745E8D4436Q28143301-D0A688D1-C6C4-4824-ACD4-154BAFD7BAA3Q28215081-8ABA5749-7862-40DA-804C-9881F93473D4Q28304889-2379F432-CC09-4462-BAB8-F540E89C2444Q28306498-13C9CB90-F661-4337-B078-80D4FC1C53AFQ28368856-7FD328DE-D4EF-4086-8B93-46E9664F57CBQ29547180-642C3E6B-FEA7-490A-A46A-4A66AD84A870Q29614788-4F5AD3DF-E638-4D8E-ACE5-00644079E14EQ29620167-2CE75914-E043-4251-BC4E-BFFC6A967ED2Q32068514-5D7476B5-7B7B-4956-B6BF-F61080D84AF5Q33782118-9CA8D413-B02C-4B25-A2B3-7FA07F14617CQ33795939-4CA83B11-40E2-41C9-8D94-505A2934643FQ34351276-A523BEF8-A349-4C3B-94A1-6CEC98E8A3F9Q34391750-7115C453-C0E3-4B77-9BF3-FD2BA6DEEB2AQ34595952-317800A8-654A-400B-864F-91C3408E76C9Q35190358-485D6DBB-08CB-438A-B83C-101F2F0F18F5Q35845347-E6E21CB8-2730-4C87-91BC-7D1B111930D5Q35874090-5797CE65-B5A2-4F45-B09D-2CA86C2A5035Q35890307-EC832299-564D-445D-8753-3E85A3EDC389Q35893644-D0DEBC4D-D294-4B34-8917-D871A6B96505Q36802956-CE334C6A-3564-461D-BB86-229DD4DE9C7AQ38342881-98E6C6E0-D08E-459C-A780-1D36411560FCQ39307853-34222CFE-A752-4F33-8EBD-DE2A63444443Q39539781-FAE62CE1-3D1B-47D2-9F4E-2D1105E9E6F3Q39676027-9A738375-2A83-4F6B-ABBF-EEBDA13B78BFQ39721955-0CD27A38-06EE-4958-9846-5D60859BF91CQ39870080-2E6AECA9-0043-4CC9-88DF-F5D34C66FC47Q39872155-4B6CC4EF-E3F6-44A9-824A-BD468F3A8FF0Q39877972-ED882757-B359-4D15-8436-56B9CBEFEE8DQ39895370-36A00DD8-A71C-4C2E-BC4D-2347C483A264Q40022618-2C9F7D10-43FA-4D5A-ABBA-961E4EB0121BQ54143822-7FC11FDA-CE98-46A5-A6FD-CFE3486A27E4
P2860
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
@en
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
@nl
type
label
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
@en
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
@nl
prefLabel
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
@en
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
@nl
P2093
P356
P1476
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro.
@en
P2093
P304
P356
10.1006/JMBI.1993.1427
P407
P577
1993-08-01T00:00:00Z